|
Non-proprietary validated LC/MS methods offer a cost-effective and timely solution for clients with drug-drug interaction (DDI) or comparison studies with established therapeutic compounds. Advion is happy to partner with new and existing clients to develop non-proprietary assays that have value to the pharmaceutical industry.
Advion specializes in method development and validation of proprietary methods for our pharmaceutical partners worldwide. Advion also has a variety of validated LC/MS methods available that are non-proprietary (see below). Simply click on the validated method name to download a method sheet (PDF) describing the anticoagulant used, accuracy and precision, and stability details for the assay.
If there is a non-proprietary method you feel we should offer, please email us at CROinfo@advion.com.
Please sign in to download or request publication documents. You must register before you log in for the first time.
| Validated Method |
Matrix |
Validated Range |
Extraction Volume |
Internal Standard |
|
Acyclovir, valaciclovir (140 kb) |
Human plasma |
10 - 1000 ng/mL |
50 µL |
Stable Label |
|
Amlodipine (135 kb) |
Human plasma |
0.1 - 10 ng/mL |
100 µL |
Analogue |
|
D-Amphetamine, L-Amphetamine (chiral) (167 kb) |
Human plasma |
0.5 - 75 ng/mL |
200 µL |
Stable Label |
|
Atomoxetine (153 kb) |
Human plasma |
0.5 - 500 ng/mL |
50 µL |
Stable Label |
|
Atorvastatin, o-hydroxyatorvastatin, p-hydroxyatorvastatin (186 kb) |
Human plasma |
0.25 - 25 ng/mL |
200 µL |
Stable Label |
| Bortezomib (VELCADE®) |
Human plasma |
Expected |
Spring 2008 |
|
Digoxin (156 kb) |
Human serum |
0.1 - 20 ng/mL |
200 µL |
Analogue |
|
Digoxin (156 kb) |
Human urine |
5 - 1000 ng/mL |
100 µL |
Analogue |
|
Donepezil (160 kb) |
Human Plasma |
0.2 - 100 ng/mL |
200 µL |
Stable Label |
|
Duloxetine (153 kb) |
Human plasma |
0.2 - 200 ng/mL |
50 µL |
Stable Label |
|
5-Fluorouracil (153 kb) |
Human plasma |
2 - 1000 ng/mL; 10 - 10000 ng/mL |
100 µL |
Stable Label |
|
Fenofibric Acid (139 kb) |
Human plasma |
20 - 10000 ng/mL |
100 µL |
Stable Label |
|
Gemcitabine (150 kb) |
Human plasma |
10 - 10000 ng/mL |
25 µL |
Stable Label |
| Glyburide |
Human PFF (non-protein bound) |
0.025 - 2 ng/mL |
100 µL |
Stable Label |
| Glyburide |
Human plasma (total) |
1 - 250 ng/mL |
200 µL |
Stable Label |
|
Imatinib, N-desmethyl imatinib (Gleevec®) (161 kb) |
Human plasma |
100 - 10000 ng/mL |
50 µL |
Stable Label |
|
Lamivudine (as part of Combivir®) (153 kb) |
Human plasma |
2 - 1000 ng/mL |
200 µL |
Stable Label |
|
Lamivudine (as part of Combivir®) (144 kb) |
Human urine |
2 - 1000 ng/mL |
200 µL |
Stable Label |
| Lamotrigine (46 kb) |
Human plasma |
Expected |
Fall 2007 |
|
|
Lovastatin, lovastatin acid (152 kb) |
Human plasma |
0.25 - 100 ng/mL |
500 µL |
Stable Label |
| LTE4 |
Human urine |
25 - 1000 pg/mL |
1000 µL |
Stable Label |
|
Methotrexate, 7-hydroxymethotrexate (181 kb) |
Human plasma |
1 - 200 ng/mL |
200 µL |
Stable Label |
|
Methotrexate, 7-hydroxymethotrexate (174 kb) |
Human urine |
50 - 1000 ng/mL |
20 µL |
Stable Label |
|
Methylphenidate, á-phenyl-á-(2-piperidyl) acetic acid (148 kb) |
Human plasma |
0.05 - 25 ng/mL |
100 µL |
Stable Label |
|
Midazolam, 1-hydroxymidazolam (173 kb) |
Human plasma |
0.1 - 100 ng/mL |
100 µL |
Stable Label |
|
Moxifloxacin (155 kb) |
Human plasma |
25 - 5000 ng/mL |
50 µL |
Stable Label |
|
Omeprazole, hydroxyomeprazole, omeprazole sulfone (148 kb) |
Human plasma |
0.5 - 500 ng/mL |
50 µL |
Stable Label |
|
Paclitaxel, 6–á–OH Paclitaxel (164 kb) |
Human plasma |
10 - 5000 ng/mL |
200 µL |
Stable Label |
|
S,S-Reboxetine (149 kb) |
Human plasma |
0.5 - 500 ng/mL |
50 µL |
Stable Label |
|
Ritonavir (151 kb) |
Human plasma |
10 - 5000 ng/mL |
50 µL |
Stable Label |
|
Rosiglitazone (161 kb) |
Human plasma |
5 - 3000 ng/mL |
25 µL |
Analogue |
| Rosuvastatin, rosuvastatin lactone, N-desmethyl rosuvastatin (190 kb) |
Human plasma |
0.5 - 100 ng/mL |
100 µL |
Stable Label |
Simvastatin, simvastatin acid (167 kb) |
Human plasma |
0.1 - 30 ng/mL |
200 µL |
Stable Label |
|
Tolterodine, 5-hydroxymethyltolterodine (174 kb) |
Human plasma |
0.2 - 50 ng/mL |
100 µL |
Stable Label |
|
Valproic acid (133 kb) |
Human serum |
1 - 100 µg/mL |
100 µL |
Stable Label |
|
Warfarin, R- and S- (chiral) (150 kb) |
Human PFF (non-protein bound) |
0.1 - 10 ng/mL |
200 µL |
Stable Label |
|
Warfarin, R- and S- (chiral) (178 kb) |
Human plasma (total) |
1 - 2500 ng/mL |
100 µL |
Stable Label |
| Zidovudine (as part of Combivir®) (170 kb) |
Human plasma |
2 - 1000 ng/mL |
200 µL |
Stable Label |
| Zidovudine (as part of Combivir®) (144 kb) |
Human urine |
2 - 1000 ng/mL |
200 µL |
Stable Label |
| Ziprasidone (140 kb) |
Human plasma |
0.5 - 150 ng/mL |
200 µL |
Stable Label |
|
